METHOD FOR PREDICTING THE CLINICAL STATUS OF PROSTATE CANCER Russian patent published in 2018 - IPC G01N33/574 G01N33/49 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncourology, and concerns the prediction of the clinical status of prostate cancer. To do this, the serum of the patient is determined before the treatment of the levels of the total prostatic antigen (total PSA) with the calibration of Hybritech. Calculate the index of staging (IS) of prostate cancer according to the formula: IS = 0.0278 * Age + 0.0478 * total PSA + Gleason index – 0.01 * V, where: Age – number of full years; total PSA – measured in ng/ml according to Hybritech calibration; Gleason index – has rank value “1”, if Gleason's index on the results of a biopsy < 7; rank value is “2”, if the Gleason index is 7 (3+4); rank value is “3” if the Gleason index is 7 (4+3); rank value of “4”, if Gleason factor > 8; V – volume of the prostate, measured in cm³. If: IS < 2.45 units, then localized indolent cancer of the prostate gland is predicted, the Gleason index < 7; IS 2.45–2.75 units, then localized prostate cancer, category T2, is predicted; average risk for the Gleason index ≥ 7; IS > 3.50 units, then aggressive cancer of the prostate gland is projected, in this case: with the IS 3.50–3.84 units. A high risk is projected for the Gleason index ≥ 7 and/or high risk category ≥ T3a; at IS of 3.85–5.75 units the Gleason index is predicted ≥ 7 and high risk category ≥ T3a; at IS > 5.75 units Gleason index is predicted ≥ 7 and category ≥ T3a.

EFFECT: invention provides preoperatively with greater reliability the stage of the tumor process in patients with PCa.

1 cl, 3 dwg, 2 tbl